STOCK TITAN

Harvard Apparatus Regenerative Technology Reports Second Quarter 2023 Financial Results

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Harvard Apparatus Regenerative Technology, Inc. announced its financial results for Q2 2023, reporting a net loss of $2.6 million compared to $1.4 million in Q2 2022. The company activated its first clinical trial site with Mayo Clinic and contracted with IQVIA as the contract research organization. They also started a Consumer Health business in Hong Kong, planning to sell anti-aging supplements in Q3 2023.
Positive
  • None.
Negative
  • None.

HOLLISTON, Mass., Aug. 14, 2023 /PRNewswire/ -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) ("Harvard Apparatus Regenerative Technology" or the "Company"), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today announced its financial results for the three and six months ended June 30, 2023.

Operating Highlights

We officially activated the first clinical trial site with Mayo Clinic and are currently screening patients in the third quarter of 2023. We have contracted with IQVIA, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, as the contract research organization (CRO) to manage our first clinical trial.

"The initiation of our first clinical study for Cellspan Esophageal Implant (CEI) marked an important milestone for HRGN," said Jerry He, Chairman and CEO of HRGN. "Our numerous preclinical studies and first-in-human E-IND study have demonstrated our technology as an effective platform for tubular organ regeneration. We look forward to testing CEI in the trial as we further our understanding of its potential benefits for patients."

In the second quarter of 2023, the Company's subsidiary in Hong Kong, Harvard Apparatus Regenerative Technology Limited, or HRGN LTD, started a Consumer Health business.

The Consumer Health business will include a broad range of products focused on anti-aging dietary supplements. The Company plans to start selling anti-aging supplements through the Hong Kong subsidiary in the third quarter of 2023. These products are marketed to the general public and initially targeted at consumers in the Greater China region through eCommerce (online sales).

"The Consumer Health business is a great way to generate additional revenue and operating cash flow from China without distracting our R&D and clinical trial efforts in the US." Commented Mr. He.

Summary of Financial Results

For the three months ended June 30, 2023, the Company reported a net loss of $2.6 million, ($0.19) per share, compared to a net loss of $1.4 million, ($0.12) per share, for the three months ended June 30, 2022. The $1.2 million year-over-year net loss increase was due primarily to clinical trial activities resulting in our first site activation.

For the six months ended June 30, 2023, the Company reported a net loss of $5.6 million, ($0.43) per share, compared to a net loss of $3.5 million, ($0.32) per share, for the six months ended June 30, 2022. The $2.1 million year-over-year net loss increase was due to clinical trial activities resulting in our first site activation and an increase in share-based compensation expense from the vesting of performance-based awards in the second quarter of 2023.

Balance Sheet and Cash and Cash Equivalents

At June 30, 2023, the Company had operating cash and short-term investments on-hand as of $4.7 million.

During the six-month period ended June 30, 2023, the Company used net cash in operations of $2.6 million and received $6.0 million from financing activities representing proceeds from private placement transactions that resulted in the issuance of 1,000,967 shares of our common stock to investors.

About Harvard Apparatus Regenerative Technology, Inc.

We are a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma or birth defects. Our technology is based on our proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs. We believe that our technology represents a next-generation solution for restoring organ function because it allows the patient to regenerate their own organ, thus eliminating the need for human donor or animal transplants, the sacrifice of another of the patient's own organs or permanent artificial implants.

We conducted the world's first successful regeneration of the esophagus in a patient with esophageal cancer in August 2017. This surgery was performed by Dr. Denis Wigle, Chair of Thoracic Surgery at the Mayo Clinic. The results were published in the Journal of Thoracic Oncology Clinical and Research Reports in August 2021. The procedure demonstrated that our technology was able to successfully regenerate esophageal tissue, including the mucosal lining, to restore the integrity, continuity and functionality of the esophageal tube. 

HRGN has 13 issued U.S. patents, 2 issued in China, 1 issued in Japan, 2 issued in Europe and 2 orphan-drug designations which can provide seven years of market exclusivity once we won the market approval.

For more information, please visit www.hregen.com and connect with the Company on  LinkedIn.

Forward-Looking Statements

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements in this press release include, but are not limited to, statements relating to the capabilities and performance of our products and product candidates; development expectations and regulatory approval of any of the Company's products, by the U.S. Food and Drug Administration, the European Medicines Agency or otherwise, which expectations or approvals may not be achieved or obtained on a timely basis or at all; and success with respect to any collaborations, clinical trials and other development and commercialization efforts of the Company's products, which such success may not be achieved or obtained on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the Company's inability to obtain needed funds in the immediate future; the Company's ability to obtain and maintain regulatory approval for its products; plus other factors described under the heading "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022 or described in the Company's other public filings. The Company's results may also be affected by factors of which the Company is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

Investor Relations Contacts

Joseph Damasio
Chief Financial Officer
774-233-7330
jdamasio@hregen.com

HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except par value and share data)




June 30,



December 31,




2023



2022




(Unaudited)





ASSETS









Current assets:









Cash and cash equivalents


$

2,140



$

1,241


Short-term investments



2,523





Prepaid research and development



259




274


Prepaid expenses and other current assets



79




79


Total current assets



5,001




1,594


Property, plant and equipment, net



39




49


Right-of-use assets, net



135




147


Deferred financing costs



544




610


Other long-term assets



62





Total assets


$

5,781



$

2,400











LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)









Current liabilities:









Accounts payable


$

372



$

682


Accrued and other current liabilities



1,476




582


Operating lease liability, current



119




99


Total current liabilities



1,967




1,363


Operating lease liability, net of current portion



18




48


Total liabilities



1,985




1,411











Commitments and contingencies









Series E convertible preferred stock, par value $0.01 per share, 5,000 shares authorized; 0 and 4,180 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively






4,180











Stockholders' equity (deficit):









Common stock, par value $0.01 per share, 60,000,000 shares authorized; 13,882,060 and 12,174,467 issued and outstanding at June 30, 2023 and December 31, 2022, respectively



139




122


Additional paid-in capital



92,172




79,698


Accumulated deficit



(88,515)




(83,011)


Total stockholders' equity (deficit)



3,796




(3,191)


Total liabilities and stockholders' equity (deficit)


$

5,781



$

2,400


 

HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per share amounts)




Three Months Ended



Six Months Ended




June 30,



June 30,




2023



2022



2023



2022


Operating expenses:

















Research and development


$

1,566



$

326



$

2,075



$

629


Selling, general and administrative



1,085




1,049




3,463




2,951


Total operating expenses



2,651




1,375




5,538




3,580



















Operating loss



(2,651)




(1,375)




(5,538)




(3,580)



















Other income, net:

















Sublease income






32







61


Other income (expense), net



37




(2)




34




(3)


Total other income, net



37




30




34




58



















Net loss



(2,614)




(1,345)




(5,504)




(3,522)


Preferred stock dividends



3




(18)




(77)




(18)


Net loss attributable to common stockholders


$

(2,611)



$

(1,363)



$

(5,581)



$

(3,540)



















Basic and diluted net loss per share


$

(0.19)



$

(0.12)



$

(0.43)



$

(0.32)



















Weighted average common shares, basic and diluted



13,785,657




11,230,525




13,000,211




10,996,996



















 

HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)




2023



2022




Six Months Ended




June 30,




2023



2022


OPERATING ACTIVITIES









Net loss


$

(5,504)



$

(3,522)


Adjustments to reconcile net loss to net cash used in operating activities:









Share-based compensation expense



2,319




512


Depreciation



23




27


Change in fair value of warrant liability






(2)


Changes in operating assets and liabilities:









Prepaid research and development



15





Prepaid expenses and other current assets






198


Deferred financing costs



66




(173)


Other long-term assets



(62)





Accounts payable



(310)




823


Accrued and other current liabilities



894




483


Net cash used in operating activities



(2,559)




(1,654)











INVESTING ACTIVITIES









Purchases of short-term investments



(2,523)





Purchases of property, plant, and equipment



(11)




(8)


Net cash used in investing activities



(2,534)




(8)











FINANCING ACTIVITIES









Proceeds from issuance of common stock



5,992




5,060


Net cash provided by financing activities



5,992




5,060


Net increase in cash and cash equivalents



899




3,398


Cash and cash equivalents at the beginning of the year



1,241




1,292


Cash and cash equivalents at the end of the period


$

2,140



$

4,690











Supplemental disclosure of non-cash activities:









Settlement of contingency matter


$



$

(3,250)


Settlement of due to Harvard Bioscience included in accrued and other current liabilities


$



$

(750)


Issuance of Series E convertible preferred stock


$



$

4,000


Purchases of property and equipment in accounts payable or accrued expenses


$

5



$


Preferred stock dividends


$

77



$

18


Conversion of preferred stock into common stock


$

4,257



$


 

 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/harvard-apparatus-regenerative-technology-reports-second-quarter-2023-financial-results-301899337.html

SOURCE Harvard Apparatus Regenerative Technology, Inc.

FAQ

What are the financial results of Harvard Apparatus Regenerative Technology for Q2 2023?

The company reported a net loss of $2.6 million.

Who is the contract research organization for Harvard Apparatus Regenerative Technology's first clinical trial?

The company has contracted with IQVIA.

What is Harvard Apparatus Regenerative Technology's new business in Hong Kong?

They started a Consumer Health business focused on anti-aging dietary supplements.

When will Harvard Apparatus Regenerative Technology start selling anti-aging supplements?

They plan to start selling in Q3 2023.

What is the current cash and cash equivalents of Harvard Apparatus Regenerative Technology?

As of June 30, 2023, the company had $4.7 million in operating cash and short-term investments.

How much cash did Harvard Apparatus Regenerative Technology use in operations for the six months ended June 30, 2023?

The company used net cash of $2.6 million in operations.

How much cash did Harvard Apparatus Regenerative Technology receive from financing activities in the six months ended June 30, 2023?

They received $6.0 million from financing activities.

How many shares of common stock were issued by Harvard Apparatus Regenerative Technology to investors?

1,000,967 shares of common stock were issued to investors.

BSTG

OTC:BSTG

BSTG Rankings

BSTG Latest News

BSTG Stock Data

63.85M
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing